Edwards Lifesciences (NYSE: EW) CVP exercises stock options and sells 619 shares

Rhea-AI Filing Summary

Edwards Lifesciences Corp executive Daniel J. Lippis, CVP, TAVR, exercised employee stock options for 619 shares of common stock at $72.68 per share and, in a related open-market transaction, sold 619 shares at $91.70 per share on July 10, 2026. Following these transactions, he holds 40,033.9103 common shares directly and 4,952 employee stock options. The activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on February 13, 2026.

Insights

Equity compensation analyst

Routine option exercise and sale under a pre-set trading plan.

CVP, TAVR Daniel J. Lippis exercised employee stock options for 619 shares at a strike price of $72.68 and sold an equal number of shares at $91.70 on July 10, 2026. This is a classic exercise-and-sell pattern, converting part of his option position into cash.

The filing shows 40,033.9103 common shares held directly after the sale and 4,952 options remaining after the exercise. A footnote states the transactions occurred under a Rule 10b5-1 trading plan adopted on February 13, 2026, indicating they were pre-scheduled rather than opportunistic. Overall, this appears to be routine personal portfolio and compensation management rather than a thesis-changing signal.

Insider Trade Summary 10b5-1

Exercise and Sale: 619 shares ($12K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Lippis Daniel J.

Role CVP, TAVR

Sold 619 shs ($57K)

Approx. gross sale proceeds $57K

Approx. exercise cost $45K

Approx. pre-tax spread $12K

Type	Security	Shares	Price	Value
Exercise	Employee Stock Option (Right to Acquire)	619	$0.00	$0.00
Exercise	Common Stock F1	619	$72.68	$45K
Sale	Common Stock F1	619	$91.70	$57K

Holdings After Transaction: Employee Stock Option (Right to Acquire) — 4,952 shares (Direct); Common Stock — 40,033.9103 shares (Direct)

Footnotes (1)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Key Figures

Shares sold: 619 shares Sale price: $91.70 per share Option exercise price: $72.68 per share +4 more

7 metrics

Shares sold 619 shares Open-market sale of common stock on July 10, 2026

Sale price $91.70 per share Price received for 619 common shares sold on July 10, 2026

Option exercise price $72.68 per share Strike price for 619 employee stock options exercised

Shares held after sale 40,033.9103 shares Direct common stock holdings following the July 10, 2026 sale

Options remaining 4,952 options Employee stock options outstanding after exercising 619 options

Rule 10b5-1 plan adoption date February 13, 2026 Date the pre-arranged trading plan governing these transactions was adopted

Option expiration date May 6, 2027 Expiration date for the employee stock option series exercised in part

Key Terms

Rule 10b5-1 trading plan, Employee Stock Option (Right to Acquire), derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Employee Stock Option (Right to Acquire) financial

"security_title: Employee Stock Option (Right to Acquire)"

derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/10/2026 - 05:04 PM Accepted by SEC EDGAR 07/10/2026 - 05:04 PM Learn about SEC filing dates

FAQ

What transaction did EW executive Daniel J. Lippis report on this Form 4?

Daniel J. Lippis reported exercising employee stock options for 619 shares of Edwards Lifesciences common stock at $72.68 per share and selling 619 shares in an open-market transaction at $91.70 per share on July 10, 2026.

How many Edwards Lifesciences (EW) shares does Daniel J. Lippis hold after these transactions?

After the reported transactions, Daniel J. Lippis directly holds 40,033.9103 shares of Edwards Lifesciences common stock. He also retains 4,952 employee stock options following the exercise of 619 options on July 10, 2026.

Were Daniel J. Lippis’s EW stock transactions made under a Rule 10b5-1 plan?

Yes. A footnote explains that the transactions reported were effected pursuant to a Rule 10b5-1 trading plan adopted by Daniel J. Lippis on February 13, 2026, indicating they were pre-arranged.

What option terms are disclosed for Daniel J. Lippis’s Edwards Lifesciences (EW) stock options?

The filing shows an Employee Stock Option$72.68 exercise price, an exercise date of May 7, 2021, and an expiration date of May 6, 2027. After exercising 619, 4,952 options remain outstanding.

What is the net effect of Daniel J. Lippis’s July 10, 2026 EW trades on his share count?

On July 10, 2026, Daniel J. Lippis exercised options and sold an equal 619 shares, resulting in a net sale of 619 shares based on the Form 4 transaction summary, while still holding over 40,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippis Daniel J.

(Last) (First) (Middle)

ONE EDWARDS WAY

(Street)

IRVINE CALIFORNIA 92614

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CVP, TAVR

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/10/2026		M(1)		619	A	$72.68	40,652.9103	D
Common Stock	07/10/2026		S(1)		619	D	$91.7	40,033.9103	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Acquire)	$72.68	07/10/2026		M			619	05/07/2021	05/06/2027	Common Stock	619	$0.0000	4,952	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 13, 2026.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.

	Linda J. Park, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)